BG65845B1 - Използване на треосулфан за поддържане състоянието на пациенти преди трансплантация на костен мозък или кръвни стволови клетки - Google Patents

Използване на треосулфан за поддържане състоянието на пациенти преди трансплантация на костен мозък или кръвни стволови клетки Download PDF

Info

Publication number
BG65845B1
BG65845B1 BG106772A BG10677202A BG65845B1 BG 65845 B1 BG65845 B1 BG 65845B1 BG 106772 A BG106772 A BG 106772A BG 10677202 A BG10677202 A BG 10677202A BG 65845 B1 BG65845 B1 BG 65845B1
Authority
BG
Bulgaria
Prior art keywords
use according
patient
threosulfan
condition
therapy
Prior art date
Application number
BG106772A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG106772A (bg
Inventor
Joachim Baumgart
Original Assignee
Medac Gesellschaft Fur Klinische Spezial Praparate Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medac Gesellschaft Fur Klinische Spezial Praparate Mbh filed Critical Medac Gesellschaft Fur Klinische Spezial Praparate Mbh
Publication of BG106772A publication Critical patent/BG106772A/bg
Publication of BG65845B1 publication Critical patent/BG65845B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
BG106772A 1999-11-05 2002-06-04 Използване на треосулфан за поддържане състоянието на пациенти преди трансплантация на костен мозък или кръвни стволови клетки BG65845B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19953517A DE19953517C1 (de) 1999-11-05 1999-11-05 Verwendung von Treosulfan zur Konditionierung von Patienten vor Knochemarktransplantation oder Blutstammzelltransplantation
PCT/EP2000/010871 WO2001032154A2 (de) 1999-11-05 2000-11-03 Verwendung von treosulfan zur konditionierung von patienten vor knochenmarktransplantation oder blutstammzelltransplantation

Publications (2)

Publication Number Publication Date
BG106772A BG106772A (bg) 2003-02-28
BG65845B1 true BG65845B1 (bg) 2010-03-31

Family

ID=7928187

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106772A BG65845B1 (bg) 1999-11-05 2002-06-04 Използване на треосулфан за поддържане състоянието на пациенти преди трансплантация на костен мозък или кръвни стволови клетки

Country Status (16)

Country Link
US (1) US7199162B1 (cg-RX-API-DMAC7.html)
EP (1) EP1227808B1 (cg-RX-API-DMAC7.html)
JP (1) JP4846151B2 (cg-RX-API-DMAC7.html)
AT (1) ATE251455T1 (cg-RX-API-DMAC7.html)
AU (1) AU777527B2 (cg-RX-API-DMAC7.html)
BG (1) BG65845B1 (cg-RX-API-DMAC7.html)
CA (1) CA2389896C (cg-RX-API-DMAC7.html)
CZ (1) CZ299701B6 (cg-RX-API-DMAC7.html)
DE (2) DE19953517C1 (cg-RX-API-DMAC7.html)
EA (1) EA004543B1 (cg-RX-API-DMAC7.html)
ES (1) ES2208435T3 (cg-RX-API-DMAC7.html)
HU (2) HU227332B1 (cg-RX-API-DMAC7.html)
NO (2) NO329616B1 (cg-RX-API-DMAC7.html)
PL (1) PL212132B1 (cg-RX-API-DMAC7.html)
UA (1) UA73961C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001032154A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
JP7431815B2 (ja) * 2018-09-26 2024-02-15 メダック ゲゼルシャフト フィア クリニッシェ スペツィアルプレパラーテ ミット ベシュレンクタ ハフトゥンク トレオスルファンの結晶形
PT4257122T (pt) 2018-09-26 2026-06-08 Medac Ges Fr Klinische Spezialprparate Mbh Liofilizado de treossulfano
EP3856252A1 (en) 2018-09-26 2021-08-04 medac Gesellschaft für klinische Spezialpräparate mbH Solution comprising treosulfan

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376546A (en) * 1991-11-04 1994-12-27 Xoma Corporation Analogs of ribosome-inactivating proteins
DE4421391C1 (de) * 1994-06-18 1995-11-30 Gsf Forschungszentrum Umwelt Verwendung von Antikörpern gegen T-Zellen zur verlängerten Immunsuppression
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting

Also Published As

Publication number Publication date
CA2389896A1 (en) 2001-05-10
ATE251455T1 (de) 2003-10-15
CZ20021562A3 (cs) 2002-10-16
EP1227808B1 (de) 2003-10-08
NO2019032I1 (no) 2019-07-23
DE50004024D1 (de) 2003-11-13
EP1227808A2 (de) 2002-08-07
CZ299701B6 (cs) 2008-10-22
AU1391801A (en) 2001-05-14
WO2001032154A2 (de) 2001-05-10
DE19953517C1 (de) 2001-08-09
NO20022109L (no) 2002-07-01
US7199162B1 (en) 2007-04-03
PL212132B1 (pl) 2012-08-31
NO329616B1 (no) 2010-11-22
ES2208435T3 (es) 2004-06-16
EA004543B1 (ru) 2004-06-24
AU777527B2 (en) 2004-10-21
HUP0203277A2 (en) 2003-01-28
PL356240A1 (en) 2004-06-28
BG106772A (bg) 2003-02-28
NO20022109D0 (no) 2002-05-02
CA2389896C (en) 2007-04-10
UA73961C2 (uk) 2005-10-17
WO2001032154A3 (de) 2002-01-24
JP2003513034A (ja) 2003-04-08
JP4846151B2 (ja) 2011-12-28
EA200200535A1 (ru) 2002-10-31
HU227332B1 (en) 2011-03-28
HUS1900041I1 (hu) 2019-10-28

Similar Documents

Publication Publication Date Title
KR100941210B1 (ko) 백금 유도체를 포함하는 제약 제제
JP6918724B2 (ja) 急性骨髄性白血病(aml)のための新規併用治療
Sjöö et al. Myeloablative and immunosuppressive properties of treosulfan in mice
Parkman et al. Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogenic bone marrow transplantation
AU2014251087A1 (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
US5049396A (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer sensitive to treatment
KR100215167B1 (ko) 면역 억제 조성물
Down et al. Relationships between ablation of distinct haematopoietic cell subsets and the development of donor bone marrow engraftment following recipient pretreatment with different alkylating drugs
Gorin et al. High dose combination chemotherapy (TACC) with and without autologous bone marrow transplantation for the treatment of acute leukaemia and other malignant diseases: Kinetics of recovery of haemopoiesis. A preliminary study of 12 cases
BG106772A (bg) Приложение на треосулфан за поддържане състоянието на пациенти преди трансплантация на костен мозъкили кръвни стволови клетки
WO2020092650A1 (en) Compositions and methods for modulating t cell exhaustion
Porter et al. Homologous marrow transplantation in rabbits after triethylenethiophosphoramide
WO2000043403A1 (en) 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes
Hess et al. Immunosuppression by succinylacetone. II. Prevention of graft-vs-host disease.
CN111388474B (zh) 密菌酯在制备用于预防和/或治疗辐射损伤的药物中的应用
Odaka et al. Immunosuppressant deoxyspergualin-induced inhibition of cell proliferation is accompanied with an enhanced reduction of tetrazolium salt
Nikkels et al. Effects of cis‐diamminedichloroplatinum (II) upon haemopoietic progenitors and the haemopoietic microenvironment in mice
Mullins et al. Bone marrow transplantation in aplastic anaemia
Kurtzberg et al. Results of the cord blood transplantation study (COBLT): Clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with inborn errors of metabolism
CN107875130A (zh) 一种吗替麦考酚酯片组合物
Parikh et al. 224: Outcomes of Unrelated Umbilical Cord Blood Transplantation in Pediatric Patients with Myelodysplastic Syndrome
rSV40 Viral 1041. Delayed Infusion of Hematopoietic Stem Cells Improves Engraftment after Low-Dose Parenterally Administered Busulfan in a Congenic Murine Transplant Model
Xenocostas et al. The impact of pre-transplant anemia on long-term survival following allogeneic bone marrow transplantation
Streilein Lymphohematopoietic reconstitution
HK1072002B (en) Platinum derivative pharmaceutical formulations